Skip to main content
Premium Trial:

Request an Annual Quote

Genesis R&D Extends Use of MorphoSys' HuCAL Antibodies for Autoimmune Rx Development

NEW YORK (GenomeWeb News) — MorphoSys today said Genesis Research and Development will continue using HuCAL-based antibodies in its drug-development research.
 
New Zealand-based Genesis will use the antibodies, developed by MorphoSys’ AbD Serotec segment, against the target molecule FGFR5 for validations and pre-clinical studies for its Zyrogen drug, which is being studied for certain autoimmune diseases, according to Genesis’ website.
 
Depending on the results of the study using the antibodies, the companies will discuss continuing the development of the therapeutic program, MorphoSys said.
 
"The collaboration with Genesis provides us with access to an innovative and scientifically attractive target molecule which may lead to lucrative future commercial opportunities for MorphoSys," MorphoSys CEO Simon Moroney said in a statement.
 
Financial terms of the agreement were not released.

The Scan

Transcriptomic, Epigenetic Study Appears to Explain Anti-Viral Effects of TB Vaccine

Researchers report in Science Advances on an interferon signature and long-term shifts in monocyte cell DNA methylation in Bacille Calmette-Guérin-vaccinated infant samples.

DNA Storage Method Taps Into Gene Editing Technology

With a dual-plasmid system informed by gene editing, researchers re-wrote DNA sequences in E. coli to store Charles Dickens prose over hundreds of generations, as they recount in Science Advances.

Researchers Model Microbiome Dynamics in Effort to Understand Chronic Human Conditions

Investigators demonstrate in PLOS Computational Biology a computational method for following microbiome dynamics in the absence of longitudinally collected samples.

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.